The invention generally relates generally to medical devices for the drainage of fluids, and more specifically to ureteral stents.
A ureter is a tubular passageway in a human body that conveys urine from a kidney to a bladder. The ureter begins with the renal pelvis and ends at the trigone region of the bladder, i.e., the triangulated area between both ureteral orifices and the bladder neck. Urine is transported through the ureter under the influence of hydrostatic pressure, assisted by contractions of muscles located within the walls (lining) of the ureter. Some patients experience a urological condition known as ureteral blockage or obstruction. Some common causes of ureteral blockage are the formation of tumors or abnormalities within the ureteral lining, or the formation and passage of kidney stones.
Ureteral stents are used to facilitate urinary drainage from the kidneys to the bladder in patients having a ureteral obstruction or injury, or to protect the integrity of the ureter in a variety of surgical manipulations. Stents may be used to treat or avoid ureter obstructions (such as ureteral stones or ureteral tumors) which disrupt the flow of urine from the kidneys to the bladder. Serious obstructions may cause urine to back up into the kidneys, threatening renal function. Ureteral stents may also be used after endoscopic inspection of the ureter.
A stent may be uncomfortable to a patient because of intramural tunnel pain, imposed by the stent itself or in combination with intraoperative trauma inflicted from device passage. Pain may also be caused by urine reflux back up the ureter during increased bladder pressure, e.g., during voiding. Further, pain may stem from trigome irritation resulting from constant irritation, imposed by the bladder anchoring features or in combination with intraoperative trauma inflicted from device passage. Moreover, discomfort may arise from flank pain, caused by reflux or kidney anchoring.
Ureteral stents typically are tubular in shape, terminating in two opposing ends: a kidney distal end and a bladder proximal end. Existing ureteral stents compensate for the motion between the kidney and bladder by employing a pair of coil end-effectors, with one effector placed in the bladder proximal end and the other in the kidney distal end. As motion occurs, the ureter slides up and down the stent body. Any other travel results in an uncurling of the end effector(s).
It is an objective of the invention to provide a patient, male or female, with a flexible device designed to maintain the patency of the ureter and enable fluid drainage while minimizing the pains and discomfort commonly associate with an in-dwelling device.
Discomfort may be related to the stent rubbing against a wall of the ureter, caused by the constant relative motion between the kidney and the bladder. This motion may be as much as 5 centimeters (cm) (approximately 2 inches) and cycles with each breath of the patient. This is equal to approximately 17,000 cycles per day, assuming 1 breath every 5 seconds. The present invention alleviates discomfort by providing a stent that, like the ureter, linearly expands and contracts in response to relative motion between the kidney and the bladder, thereby reducing friction caused by a stent rubbing against a wall of the ureter.
In one aspect, the invention features a ureteral stent having an elongated member defining a lumen. The member has a solid sidewall defining a spiral-shaped opening such that the member is linearly expandable along a longitudinal axis of the lumen. A distal retention structure is connected to a distal end of the elongated member for retention in a kidney, and a proximal retention structure is connected to a proximal end of the elongated member for retention in a bladder.
One or more of the following features may also be included. The member includes a spring having a spring force of less than one pound. The member includes a wire spring. The wire spring includes a metal alloy, that may include at least one of titanium, nickel, copper, cobalt, vanadium, and iron. The metal alloy includes nitinol. The wire spring is coated with a polymer. The polymer includes at least one of urethane, nylon, thermoplastic polyurethane (TPU), thermoplastic polyester elastomer, polyethyl, and silicone.
The stent has an elongated member including a tube having the solid sidewall and defining the lumen. The spiral-shaped opening is defined by a slit formed in the sidewall of the tube. The elongated member may include a polymer, such as at least one of urethane, nylon, TPU, thermoplastic polyester elastomer, polyethyl, and silicone.
The elongated member includes an inner liner and an outer cover. A wire spring is sandwiched between the inner liner and the outer cover, with the spiral-shaped opening being defined by slits formed in the inner liner and the outer cover, between a plurality of coils of the wire spring. The wire spring includes a metal alloy including, e.g., at least one of titanium, nickel, copper, cobalt, vanadium, and iron. The metal alloy includes nitinol. At least one of the inner liner and the outer cover includes a polymer. The polymer includes at least one of urethane, nylon, TPU, thermoplastic polyester elastomer, polyethyl, and silicone.
A removable introducer is sized for placement within the lumen.
In another aspect of the invention, a ureteral stent includes an elongated member defining a lumen, the member having a solid sidewall with at least one slit formed therein such that the member is linearly expandable along a longitudinal axis of the lumen. A distal retention structure is connected to a distal end of the elongated member for retention in a kidney, and a proximal retention structure is connected to a proximal end of the elongated member for retention in a bladder.
In yet another aspect of the invention, a method of facilitating urinary drainage from a kidney to a bladder in a patient that reduces discomfort to the patient includes positioning a ureteral stent in a ureter of a patient, the ureteral stent having an elongated member defining a lumen, the member having a solid sidewall defining a spiral-shaped opening such that the member is linearly expandable along a longitudinal axis of the lumen, a distal retention structure connected to a distal end of the elongated member for retention in the kidney, and a proximal retention structure connected to a proximal end of the elongated member for retention in the bladder. The elongated member is allowed to linearly expand and contract between an expanded position and a retracted position, based on at least one of: relative positioning of organs within the patient, a breathing pattern of the patient, and relative positions of the kidney and the bladder. In addition, the elongated member can be biased to the retracted position.
In yet another aspect of the invention, a method of manufacturing a linearly expandable ureteral stent includes providing an elongated member defining a lumen, the member having a solid sidewall defining a spiral-shaped opening such that the member is linearly expandable along a longitudinal axis of the lumen. The stent also includes a distal retention structure and a proximal retention structure. The distal retention structure is connected to a distal end of the elongated member, and the proximal retention structure is connected to a proximal end of the elongated member.
The following features may be included. Providing the elongated member includes providing a wire spring. Providing the wire spring includes coating the wire spring with a polymer. Providing the wire spring includes sandwiching the wire spring between an inner lining and an outer cover. The inner lining and outer cover include extruded sheets. The inner lining and outer cover are shrunk, and slits are formed through the inner lining and outer cover between a plurality of coils of the wire spring. The inner lining and the outer cover are melted, and slits are formed through the inner lining and outer cover between a plurality of coils of the wire spring. The elongated member is provided by forming a tube including a polymer, and forming a spiral slit through the tube.
In yet another aspect of the invention, a method of placing a ureteral stent in a patient includes providing a ureteral stent. The ureteral stent includes an elongated member defining a lumen, the member having a solid sidewall defining a spiral-shaped opening such that the member is linearly expandable along a longitudinal axis of the lumen. The ureteral stent also includes a distal retention structure connected to a distal end of the elongated member, and a proximal retention structure connected to a proximal end of the elongated member. The ureteral stent is inserted into a ureter of the patient. The ureteral stent is positioned in the patient with the distal retention structure substantially within the kidney of the patient, the elongated member substantially within the intramural tunnel portion of the ureter, and the proximal retention structure substantially within the bladder of the patient. In a detailed embodiment, the ureteral stent can further include a removable introducer sized to fit within the lumen and inserting the ureteral stent includes inserting the stent with the removable introducer into the ureter.
In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating the principles of the invention.
The invention features temporary ureteral stents that, when positioned within the ureter of a patient, significantly reduce discomfort to the patient. As used herein, proximal refers to the end of a stent closest to a medical professional when placing a stent in a patient. As used herein, distal refers to the end of a stent furthest from a medical professional when placing a stent in a patient.
Referring to
Distal retention structure 125 and proximal retention structure 135 can be fabricated of materials such as nylon, polyurethane, or the like. Heat bonding of these materials to elongated member 140 is conveniently accomplished by, for example, using an RF heat source as is commonly employed for plastic tubes and catheters. The desired shape of distal and proximal retention structures 125, 135 can be formed by injection molding or extrusion. They can also be heat-formed, for example, by flaring the working piece over an anvil of an appropriate shape, with the application of heat. The shape of distal retention structure 125 can be, for example, a coil, a pig-tail coil, J-shaped, or a helical coil. The shape of proximal retention structure 135 can be, for example, a coil, a pig-tail coil, J-shaped or a helical coil. In the illustrated embodiment, both distal and proximal retention structures 125, 135 are J-shaped.
Referring to
Elongated member 140 can be manufactured by, for example, injection molding or extrusion and optionally a combination of subsequent machining operations. Extrusion processes, for example, can be used to provide a uniform shape, such as a single monolithic tube. Spiral-shaped opening 160 can be created in the desired locations by a subsequent machining operation.
Referring also to
In use, elongated member 140 can expand linearly up to 2 inches to expanded length L1, to provide comfort to the patient by compensating for at least one of: relative positioning of organs within the patient, a breathing pattern of the patient, and relative positions of kidney 110 and bladder 115. Because of the possibility of linear expansion, a physician may be able to select ureteral stent 120 with a smaller size than would be required with a conventional stent.
Referring to
Spring 315 has a plurality of coils 320 having, in some embodiments, a spring force less than one pound. Spring 315 includes a wire 325 formed from a superelastic material. Materials with superelastic properties make it possible to conFIG. a component into a particular shape, such as a coil or a sleeve, and then modify reversibly the geometry of the component, such as by straightening it out. Once the device is straightened, after removal of the straightening force, the component reverts spontaneously to its predetermined configuration, thereby regaining its former geometry. In so doing, the component provides a biasing force back to its original configuration.
Superelastic materials can include alloys of In—Ti, Fe—Mn, Ni—Ti, Ag—Cd, Au—Cd, Au—Cu, Cu—Al—Ni, Cu—Au—Zn, Cu—Zn—Al, Cu—Zn—Sn, Cu—Zn—Xe, Fe3Be, Fe3Pt, Ni—Ti—V, Fe—Ni—Ti—Co, and Cu—Sn. Preferably, wire 325 includes a superelastic material comprising a nickel and titanium alloy, known commonly as nitinol, available from Memory Corp. of Brookfield, Conn. or SMA Inc. of San Jose, Calif. The ratio of nickel and titanium in nitinol can be varied. Examples include a ratio of about 50% to about 52% nickel by weight, or a ratio of about 48% to about 50% titanium by weight. Nitinol has shape retention properties in its superelastic phase.
Wire 325 can have a coating 330 including a biocompatible material, such as a polymer like urethane, nylon, TPU, thermoplastic polyester elastomer, polyethyl, or silicone. Coating 330 can be applied to wire 325 by various methods, such as spray coating or painting.
Ureteral stent 300 has an expanded position (see, e.g.,
Referring to
Inner lining 515 and outer cover 520 are deformed at elevated temperatures to fully surround wire spring 510. For example, inner lining 515 and outer cover 520 can be shrunk by, e.g., exposure to a heat lamp. Alternatively, inner lining 515 and outer cover 520 can be melted by, e.g., heating in an oven. After deformation, a plurality of slits 525 are formed through inner lining 515 and outer cover 520 between coils 512 to form an elongated member 530. Elongated member 530 is linearly expandable along a longitudinal axis 535 of a lumen 540 extending through elongated member 530. Elongated member 530 is connected at a distal end 545 to a distal retention structure 125, and at a proximal end 555 to a proximal retention structure 135.
Referring to
Referring to
Referring to
Once the surgeon has achieved the desired positioning of stent 120, guide wire 710 is removed, while holding the pusher stationary to maintain stent 120 in position. Finally, the pusher is removed from within the patient, leaving stent 120 in place. Using this method, the stent of the invention can be precisely positioned within ureter 105 of the patient. The method can also be used to accurately position proximal retention structure 135 in bladder 115, and distal retention structure 125 within kidney 110.
In one embodiment of the invention, the guide wire, pusher, and stent are inserted into ureter 105 percutaneously through a surgical opening. In another embodiment, they are inserted into the ureter via the urinary tract of the patient.
While the invention has been particularly shown and described with reference to specific preferred embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
This application is a divisional of U.S. patent application Ser. No. 12/241,450, entitled “Linearly Expandable Ureteral Stent,” filed September 30, 2008, now U.S. Pat. No. 9,060,888, which is a divisional of U.S. patent application Ser. No. 10/283,873, entitled “Linearly Expandable Ureteral Stent,” filed October 30, 2002, now abandoned, both of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
550238 | Allen, Jr. | Nov 1895 | A |
3695021 | Ormerod et al. | Oct 1972 | A |
4503569 | Dotter | Mar 1985 | A |
4531933 | Norton et al. | Jul 1985 | A |
4643716 | Drach | Feb 1987 | A |
4660560 | Klein | Apr 1987 | A |
4671795 | Mulchin | Jun 1987 | A |
4681570 | Dalton | Jul 1987 | A |
4813925 | Anderson, Jr. et al. | Mar 1989 | A |
4874360 | Goldberg et al. | Oct 1989 | A |
5057114 | Wittich et al. | Oct 1991 | A |
5059169 | Zilber | Oct 1991 | A |
5098440 | Hillstead | Mar 1992 | A |
5116309 | Coll | May 1992 | A |
5129910 | Phan et al. | Jul 1992 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5514176 | Bosley, Jr. | May 1996 | A |
5531741 | Barbacci | Jul 1996 | A |
5554189 | De La Torre | Sep 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5562678 | Booker | Oct 1996 | A |
5572819 | Topinka et al. | Nov 1996 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5613973 | Jackson et al. | Mar 1997 | A |
5647843 | Mesrobian et al. | Jul 1997 | A |
5681274 | Perkins et al. | Oct 1997 | A |
5782916 | Pintauro et al. | Jul 1998 | A |
5789047 | Sasaki et al. | Aug 1998 | A |
5795319 | Ali | Aug 1998 | A |
5814006 | Planz | Sep 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5944701 | Dubrul | Aug 1999 | A |
5962007 | Cooper et al. | Oct 1999 | A |
5964744 | Balbierz et al. | Oct 1999 | A |
6019779 | Thorud et al. | Feb 2000 | A |
6027516 | Kolobow et al. | Feb 2000 | A |
6059825 | Hobbs et al. | May 2000 | A |
6171338 | Talja et al. | Jan 2001 | B1 |
6214042 | Jacobsen et al. | Apr 2001 | B1 |
6241691 | Ferrera et al. | Jun 2001 | B1 |
6258119 | Hussein et al. | Jul 2001 | B1 |
6306105 | Rooney et al. | Oct 2001 | B1 |
6332892 | Desmond, III et al. | Dec 2001 | B1 |
6395021 | Hart et al. | May 2002 | B1 |
6458145 | Ravenscroft et al. | Oct 2002 | B1 |
6620202 | Bottcher et al. | Apr 2003 | B2 |
6558349 | Kirkman | May 2003 | B1 |
6569150 | Teague et al. | May 2003 | B2 |
6648912 | Trout, III et al. | Nov 2003 | B2 |
6685744 | Gellman et al. | Feb 2004 | B2 |
6719804 | St Pierre | Apr 2004 | B2 |
6733536 | Gellman | May 2004 | B1 |
6887215 | McWeeney | May 2005 | B2 |
6913625 | Segura et al. | Jul 2005 | B2 |
6929664 | Kolb | Aug 2005 | B2 |
6976973 | Ruddell et al. | Dec 2005 | B1 |
7041139 | Bluni et al. | May 2006 | B2 |
7044981 | Liu et al. | May 2006 | B2 |
7166134 | Datta et al. | Jan 2007 | B2 |
7169187 | Datta et al. | Jan 2007 | B2 |
7320674 | Ruddell et al. | Jan 2008 | B2 |
7507218 | Aliski et al. | Mar 2009 | B2 |
7550012 | Lavelle | Jun 2009 | B2 |
8007702 | Gellman | Aug 2011 | B2 |
8241548 | Gellman | Aug 2012 | B2 |
8568643 | Gellman | Oct 2013 | B2 |
9017395 | Peckham | Apr 2015 | B2 |
20010003801 | Strecker | Jun 2001 | A1 |
20010053936 | Whitmore | Dec 2001 | A1 |
20020177899 | Eum et al. | Nov 2002 | A1 |
20020183852 | McWeeney | Dec 2002 | A1 |
20030040803 | Rioux et al. | Feb 2003 | A1 |
20030060870 | Reever | Mar 2003 | A1 |
20030163204 | Rix | Aug 2003 | A1 |
20030171708 | Segura et al. | Sep 2003 | A1 |
20030176831 | Gellman et al. | Sep 2003 | A1 |
20030181842 | Gellman | Sep 2003 | A1 |
20030191492 | Gellman et al. | Oct 2003 | A1 |
20030195456 | Robertson | Oct 2003 | A1 |
20030199805 | McWeeney | Oct 2003 | A1 |
20050131547 | Segura et al. | Jun 2005 | A1 |
20090030363 | Gellman | Jan 2009 | A1 |
20100072659 | Gellman | Mar 2010 | A1 |
20120285607 | Gellman | Nov 2012 | A1 |
20180125684 | DeGraaf | May 2018 | A1 |
Number | Date | Country |
---|---|---|
101 55 767 | May 2003 | DE |
2001089415 | Nov 2001 | WO |
2005102217 | Nov 2005 | WO |
Entry |
---|
Non-Final Office Action for U.S. Appl. No. 12/241,450, dated Sep. 16, 2010, 13 pages. |
Non-Final Office Action Response for U.S. Appl. No. 12/241,450, filed Jan. 21, 2011, 12 pages. |
Non-Final Office Action for U.S. Appl. No. 12/628,304, dated Dec. 10, 2010, 13 pages. |
Non-Final Office Action for U.S. Appl. No. 12/241,450, dated Jun. 22, 2010, 6 pages. |
Office Action Response for U.S. Appl. No. 12/241,450, filed Jul. 22, 2010, 2 pages. |
Final Office Action Response for U.S. Appl. No. 12/241,450, filed May 9, 2011, 12 pages. |
Advisory Action for U.S. Appl. No. 12/241,450, dated May 19, 2011, 3 pages. |
Final Office Action for U.S. Appl. No. 12/241,450, dated Mar. 10, 2011, 14 pages. |
Notice of Allowance for U.S. Appl. No. 12/628,304, dated Apr. 28, 2011, 15 pages. |
U.S. Appl. No. 60/136,177, filed May 27, 1999, Tremaglio. |
Thomas W. Duerig et al. “Superelastic Nitinol for Medical Devices,” Medical Device Link. [online] [retrieved on Aug. 7, 2008] Retrieved from the Internet <URL: http://www.devicelink.com/mpb/archive/97/03/003.html>. |
Mardis et al., “Ureteral Stents,” Urologic Clinics of North America, vol. 15, No. 3, Aug. 1988, pp. 471-479. |
Kulkarni et al., “An analysis of the cost effectiveness of a new thermo expandable ureteric stent MEMOKATH® 051,” presented at the 1999 World Congress on Endourology at the Ashford Hospital, Ashford, Middlesex, United Kingdom, 1 page. |
Kulkarni etal., “A critical evaluation of the indications and long term results of the application of MEMOKATH® 051,” presented at the 2000 World Congress on Endourology at the Ashford and St. Peter's Hospital, Ashford, Middlesex, United Kingdom, 1 page. |
International Search Report for International Application No. PCT/US03/34214 dated Apr. 15, 2004. |
Barwart et al., “An evaluation of the transition temperature range of super-elastic orthodontic NiTi springs using differential scanning calorimetry,” European Journal of Orthodontics 21:497-502 (1999). |
Notice of Allowance for U.S. Appl. No. 13/205,440, dated Apr. 13, 2012, 23 pages. |
Non-Final Office Action for U.S. Appl. No. 12/241,450, dated Oct. 31, 2013, 13 pages. |
Notice of Allowance for U.S. Appl. No. 13/556,864, dated Jun. 28, 2013, 8 pages. |
Final Office Action for U.S. Appl. No. 12/241,450, dated Mar. 4, 2014, 10 pages. |
Number | Date | Country | |
---|---|---|---|
20100076574 A1 | Mar 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12241450 | Sep 2008 | US |
Child | 12628289 | US | |
Parent | 10283873 | Oct 2002 | US |
Child | 12241450 | US |